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GPIba, a glycoprotein component of the GPIb-IX-
V complex, serves as a platelet membrane receptor
that mediates adhesion to von Willebrand factor
normally present in the vascular subendothelium.
Recent data have demonstrated that GPIba is not
restricted to platelets, but is also expressed by endo-
thelium in vitro. In this study, we describe the expres-
sion and distribution of GPIba in normal adult and
neonatal human skin. GPIba is present, as detected
by immunohistochemistry, on endothelial cells and on
highly dendritic cells localized within the perivascular
space, dermal–epidermal junction, and reticular
dermis. By dual-labeling immunofluorescence and
confocal microscopy, GPIba-positive cells within the
The glycoprotein GPIb-IX-V complex is a membranereceptor present on the surface of platelets. It iscomposed of four leucine-rich glycoproteins: thedisulfide-linked 135 kDa Ibα and 25 kDa Ibβ chains;and GPIX (22 kDa) and GPV (83 kDa), which are
noncovalently associated (Berndt et al, 1985; Lopez and Dong,
1997). Glycoproteins Ib and IX are present in equal numbers on
the surface of intact platelets, whereas GPV is represented in the
complex in only half the quantity of the other components
(Modderman et al, 1992). Whether GPIX interacts primarily with
GPIbβ, or with GPIbα, remains controversial (Lopez et al, 1994;
Wu et al, 1996).
Initial insight into the functional significance of the GPIb-IX-V
complex came from studies of the Bernard–Soulier syndrome,
where the membrane complex is congenitally absent or structurally
defective (Jenkins et al, 1976; Roth, 1996). Affected individuals
demonstrate a bleeding disorder characterized by thrombocyto-
penia, enlarged platelets with markedly decreased adhesion to rabbit
aortic subendothelium (Weiss et al, 1974; Caen et al, 1976), and
decreased responsiveness to thrombin (DeMarco et al, 1991). The
amino-terminal extracytoplasmic region of GPIbα displays closely
associated binding sites for both von Willebrand factor and thrombin
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dermal interstitium are demonstrated to represent
factor XIIIa-positive dermal dendrocytes. In organ
cultures of neonatal human foreskin, mast cell
degranulation induced by either substance P or com-
pound 48/80 resulted in transiently increased GPIba
expression by dermal dendrocytes. Because the GPIb-
IX-V complex plays a part in regulating hemostasis
and may be important for cellular interactions with
extracellular matrix molecules, these data provide
additional insight into the potential function of FXIIIa-
positive dermal dendrocytes in skin remodeling and
repair. Key words: glycoprotein GPIba/mast cell secretagog-
ues/recombinant tumor necrosis factor-a. J Invest Dermatol
113:272–276, 1999
(Ruggeri, 1991; Jandrot-Perrus et al, 1996), whereas the cytoplasmic
region of GPIbα interacts with the cell cytoskeleton through at
least two actin-binding proteins (Andrews and Fox, 1992; Takafuta
et al, 1998). Taken collectively, these observations suggest that the
GPIb-IX-V complex is important in mediating platelet adhesion
to von Willebrand factor at subendothelial sites affected by vessel
injury, and may be important in thrombin-induced platelet
aggregation.
Recently, all four GPIb-IX-V components also have been
documented to be expressed by human umbilical vein and tonsillar
endothelial cells (Sprandio et al, 1988; Konkle et al, 1990; Wu et al,
1997). The complex is capable of mediating adhesion of endothelial
cells to a von Willebrand factor substratum (Beacham et al,
1997). Moreover, certain breast carcinoma cell lines are capable of
expressing a GPIbα-related polypeptide (Oleksowicz et al, 1997).
We now report the novel findings that the GPIb-IX-V complex
component GPIbα is expressed by extravascular dermal cells
with phenotypic characteristics of dermal dendrocytes. We also
demonstrate that mast cell secretion appears to regulate this
expression.
MATERIALS AND METHODS
Skin specimens Normal adult skin (breast, n 5 4, abdomen, n 5 2,
and face, n 5 1) was obtained from elective plastic surgery, and neonatal
human foreskin (n 5 10) was obtained from elective circumcisions.
Antibodies, reagents, and cytokines IB1, a mouse monoclonal anti-
body directed against glycoprotein GPIbα, was kindly provided by Dr.
Zaverio Ruggeri (Scripps Institute, La Jolla, CA). Other antibodies used
were: rabbit polyclonal antibody against human factor XIIIa (Calbiochem-
Novabiochem, San Diego, CA); rabbit polyclonal control IgG (Biogenex,
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Figure 1. Characterization of GPIba-reactive dendritic cells in normal adult human skin. Immunohistochemistry for GPIbα demonstrates
numerous positive cells with highly dendritic contours (arrows) within the superficial dermis (A), with concentration directly beneath the epidermis (e) (B) and
about superficial vessels (v) lined by GPIbα-positive endothelium (A, C). By transmission electron microscopy (D) and correlative immunoelectron microscopy
(E), GPIbα reactivity is restricted to interstitial cells characterized by elongate membranous flaps which in cross-section resembled dendrites and averaged
20–30 µm in length (arrowheads). Inset shows typical dendritic profile at higher magnification (insets: D, X12,000; E, X16,500). Note cytoplasmic and possible
cell membrane immunoreactivity in E (unstained; Nu 5 nucleus). Cells similar in contour to GPIbα-reactive dermal dendrocytes (F) also react for FXIIIa in
adjacent tissue sections (G); arrowheads denote elongated dendrite-like extensions. Co-expression of GPIbα and FXIIIa reactivity in dermal dendrocytes was
achieved using confocal microscopy (H 5 GPIbα channel, I 5 FXIIIa channel). Scale bars: (A–C) 25 µm; (D) 2 µm; (E) 1 µm; (F, G) 10 µm; (H, I) 5 µm.
San Ramon, CA); mouse monoclonal antibody against: (i) CD31/PECAM-
platelet endothelial cell adhesion molecule (Immunotech, Westbrook, ME);
(ii) CD34/human progenitor cell antigen (Becton Dickinson Immunocyto-
metry Systems, San Jose, CA); (iii) E-selectin/CD 62E (Becton Dickinson);
(iv) human mast cell tryptase (Chemicon, Temecula, CA); and (v) irrelevant
control mouse IgG1 antibody (Dako, Carpinteria, CA).
Fluorescent antibodies and reagents consisted of fluorescein-conjugated
donkey anti-rabbit IgG, Texas Red-conjugated donkey anti-rabbit IgG,
fluorescein-conjugated donkey anti-mouse IgG (Accurate Scientific,
Westbury, NY), avidin-conjugated fluorescein, and avidin-conjugated Texas
Red (Leinco Technologies, Ballwin, MO).
Mast cell degranulating agents consisted of compound 48/80 and
substance P (Sigma, St Louis, MO). Recombinant human tumor necrosis
factor (TNF)-α (R&D Systems, Minneapolis, MN) was used in the
following concentrations: 10, 100, and 1000 U per ml.
Immunohistochemistry Acetone-fixed cryosections (5 µm) from
normal adult skin and neonatal foreskin were stained using a three-step
immunoperoxidase method employing avidin–biotin horseradish peroxidase
(Vector Laboratories, Burlingame, CA). Briefly, tissue sections were
incubated with either primary monoclonal antibodies (anti-human GPIbα
antibody concentration 10 µg per ml) or isotype-matched control antibody
overnight at 4°C. After washing in phosphate-buffered saline, a species-
specific biotinylated antibody was applied for 30 min at room temperature
as the secondary layer, followed by an avidin–biotin horseradish peroxidase
complex for 30 min at room temperature. Immunoreactivity was then
revealed using 3,39 diaminobenzidine (Sigma) with light counterstaining
using Gill’s Hematoxylin No. 1 (Fisher Scientific, Malvern, PA).
Dual-labeling immunofluorescence Mouse monoclonal antibody
against GPIbα (40 µg per ml) was incubated on acetone-fixed cryostat
sections overnight at 4°C. After thorough washing, biotinylated horse anti-
mouse polyclonal antibody (Vector Labs) was then added, followed by
avidin-conjugated Texas Red. For factor XIIIa colocalization, rabbit
polyclonal antibody against human factor XIIIa (1 : 500) was added for
1 h at room temperature followed by fluorescein-conjugated donkey anti-
rabbit IgG for 30 min at room temperature. When both antibodies to be
colocalized were mouse monoclonal antibodies, i.e., GPIbα and CD31 or
GPIbα and CD34, mouse monoclonal antibody against GPIbα was always
incubated overnight at 4°C, followed by a rabbit anti-mouse polyclonal
antibody (Dako) and finally a donkey anti-rabbit Texas Red conjugate was
added. Then, the second mouse antibody (CD31 or CD34) was incubated
for an hour at room temperature, followed by a fluorescein-conjugated
donkey anti-mouse antibody.
Negative controls consisted of substitution of primary antibody steps
with mouse and rabbit irrelevant antibodies to rule out potential nonspecific
primary antibody binding. Potential cross-reactive binding of secondary
biotinylated and/or fluorescent antibodies was ruled out by switching of
these labels, i.e., mouse Ibα antibody was followed by fluorescein-
conjugated donkey anti-rabbit and human factor XIIIa antibody was
followed by biotinylated horse anti-mouse and avidin-fluorescein. When
primary antibodies of the same species were used, the possibility of
secondary antibody exchange was ruled out by substitution of one of the
primary antibodies with an antibody that would bind to a completely
different site in the skin, i.e., GPIbα and CD1a.
Confocal microscopy Dual labeling immunofluorescence for GPIbα
and factor XIIIa was performed on normal adult skin using 20 µm sections,
as described above, and the results were analyzed by a BioRad MRC 600
confocal microscope. Three images were consolidated over this range to
enhance appreciation of dendritic cell contour.
Electron microscopy Routine electron microscopy was done as previ-
ously described (Sueki et al, 1993). For immunoelectron microscopy, fresh
frozen normal adult skin (5 µm sections) was fixed for 10 min with 4%
paraformaldehyde in 0.1 M phosphate buffer pH 7.4 and washed in
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Figure 2. Effects of mast cell degranulation on dermal dendritic
cells coexpressing Factor XIIIa and GPIba. Co-expression of these
molecules is observed in dendritic cells (arrows) in the perivascular interstitium;
note that endothelial cells within vessels (v) also stain for GPIbα (B) but not
for factor XIIIa (A). Immunohistochemistry for GPIbα in neonatal foreskin
organ culture at baseline (C) and 24 h after substance P-induced mast cell
degranulation (D). Immunoreactivity for GPIbα on perivascular and
interstitial dermal dendritic cells, as compared with baseline and control
explants, is significantly increased 24 h after mast cell degranulation. Scale bar:
20 µm (A–D).
phosphate-buffered saline. Immunohistochemistry for GPIbα was per-
formed as described above and after 3,39 diaminobenzidine development,
the slides were refixed in 2% glutaraldehyde at 4°C overnight and then
processed for electron microscopy using inverted beem capsules.
Organ culture experiments Explants 2–3 mm wide were prepared
from neonatal foreskin specimens (n 5 10) and normal adult skin (abdomen
n 5 1 and breast n 5 1) and incubated in RPMI 1640 media containing
2 mM L-glutamine, 10% fetal bovine serum, 100 IU penicillin per ml and
100 µg streptomycin per ml in a Falcon 12 well plate with the epidermis
facing up. A total of six replicate experiments were performed to evaluate
the effects of (i) mast cell degranulation, and (ii) recombinant TNF-α on
the expression of GPIbα.
For studies of mast cell degranulation, explants were cultured for different
periods of time (1, 6, 24, and 48 h) with medium containing the
degranulating agents: compound 48/80 (0.1 and 1 mg per ml) and
substance P (5 3 10–4 M final concentration). For studies with recombinant
TNF-α (rTNF-α), explants were exposed to different concentrations of
the cytokine (10, 100, 1000 U per ml) for varying times (6, 24, 48 h). To
evaluate mast cell degranulation and TNF-α effect, immunohistochemistry
was performed to detect mast cell tryptase content and E-selectin expression,
respectively, as previously described (Kaminer et al, 1991; Walsh et al, 1991).
Cell quantitation Five square millimeters of dermal area were evaluated
for each experimental condition in the mast cell degranulation experiments.
Areas were selected which contained the most abundant and prominently
stained dendrocyte populations. Only cells containing a nucleus stained
by hematoxylin surrounded by a positive rim of immunohistochemical
reactivity were enumerated. The significance of differences was determined
by a paired Student’s t test (two-tailed).
RESULTS
Distribution and phenotypic identification of GPIba in
normal human skin In normal adult skin and in neonatal
foreskin, GPIbα reactivity was restricted to interstitial cells with
highly dendritic contours, as well as to endothelium lining dermal
vessels (Fig 1A–C) within the superficial dermis. These dendritic
cells tended to be most concentrated directly beneath the epidermal
layer (Fig 1B) and about microvessels of the superficial plexus
(Fig 1C). The cells consistently showed delicate dendrite-like
extensions, 20–30 µm in length, that originated from their cell
bodies. Transmission electron microscopy examining serial sections
demonstrated these extensions to represent cross-sections through
thin membranous flaps which at their thinnest dimension averaged
100 nm in thickness (Fig 1D), and thus had characteristics previously
described in detail for ‘‘dermal dendrocytes’’ (Sueki et al, 1993,
1995). Moreover, GPIbα immunoreactivity was confirmed to be
cytoplasmic and possibly membrane-associated only in cells with
this ultrastructural appearance (Fig 1E). Adjacent sections
immunostained for GPIbα (Fig 1F) or FXIIIa (Fig 1G) showed
apparent coexpression by dermal dendrocytes, and this impression
was confirmed using confocal microscopy (Fig 1H, I), where
consolidated images over a 20 µm span enhanced appreciation of
dendritic cell contour. GPIbα/FXIIIa-positive dermal dendrocytes
also showed variable reactivity for CD34 (data not shown). No
positively stained epidermal dendritic cells were observed.
Expression of GPIba-positive cells in organ culture after
mast cell degranulation FXIIIa-positive dermal dendrocytes
coexpressing GPIbα, as confirmed by dual-label immunofluores-
cence (Fig 2A, B), were next evaluated to determine the effects
of mast cell degranulation, which has been previously shown to
induce FXIIIa expression in these cells (Sueki et al, 1993). Mast
cell degranulation elicited by either compound 48/80 or substance
P and confirmed immunohistochemically at 1 h by tryptase
depletion, resulted in increased number and staining intensity of
immunoreactive GPIbα-positive dermal dendrocytes by 6 h. This
effect reached a maximum by 24 h (Fig 2C, D), and returned to
baseline by 48 h (data not shown). At 24 h, the number of positive
cells in control explants averaged 33 6 6.5 (range 24–38), whereas
the number in experimental explants averaged 48.8 6 8.9 (range
38–58) (p 5 0.024). Control cultures failed to demonstrate similar
changes at any time-point. Addition of various concentrations of
rTNF-α, also previously shown to increase FXIIIa expression in
dermal dendrocytes by immunohistochemistry (Sueki et al, 1993),
failed to alter immunoreactivity for GPIbα at any timepoint
examined, despite induction of endothelial E-selectin expression,
indicating its biologic efficacy (Walsh et al, 1991).
DISCUSSION
In this study, we demonstrate the novel findings that GPIbα is (i)
expressed by FXIIIa-positive and CD34-positive subpopulations of
dermal dendrocytes in normal human skin, and (ii) is transiently
upregulated as a consequence of mast cell degranulation by a
mechanism potentially independent of TNF-α.
FXIIIa-positive dermal dendrocytes are now recognized to be
distinctive dermal cells separate from truly dendritic monocyte-
macrophages primarily involved in antigen presentation (Sontheimer
and Tharp, 1991; Murphy and Liu, 1997). Indeed, three-dimensional
reconstructions have shown that FXIIIa-positive dermal dendrocytes
display dendritic contours only in two-dimensional planes, as a result
of perpendicular sectioning of thin membrane bound flaps which
protrude from the cell body (Sueki et al, 1993, 1995). Moreover,
perivascular FXIIIa-positive dermal dendrocytes are intimately
associated with mast cells (Sueki et al, 1993) which we have shown
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Figure 3. Schematic representation
of GPIb-IX-V complex and its
components (modified fromLopezand
Dong, 1997). Note the leucine-rich
domain (LRD) located nearby the ligand-
binding sites (LBS) for both von Willebrand
factor and thrombin in the amino-terminal
extracytoplasmic region of the GPIbα
molecule.
to synthesize, store, and secrete TNF-α upon degranulation (Klein
et al, 1989; Walsh et al, 1991). Increased FXIIIa expression by dermal
dendrocytes is observed in skin explants within 24 h after mast cell
degranulation or addition of rTNF-α, suggesting the possibility of
mast cell-induced dendrocyte activation (Sueki et al, 1993). These
observations have led to the speculation that, despite expression of
certain monocyte lineage epitopes and ability to present antigens in
in vitro conditions (Nestle et al, 1998), dermal dendrocytes may be
functionally heterogeneous and play a potentially important part in
collaboration with mast cells in cutaneous hemostasis and repair via
production of FXIIIa that stabilizes fibrin and fibronectin macro-
molecular complexes (Sueki et al, 1993).
We have shown that mast cells contain and release TNF-α, and
that rTNF-α, in addition to its ability to influence FXIIIa reactivity
in dermal dendrocytes, results in GPIbα mRNA and protein upregul-
ation in cultured umbilical vein endothelial cells (Konkle et al, 1990;
Rajagopalan et al, 1992). In this study, however, rTNF-α did not
result in similar effects on FXIIIa-positive dermal dendrocytes in the
concentrations employed. In addition to the possibility that dermal
dendrocytes and microvascular endothelium may respond
differently to TNF-α with regard to GPIbα expression, technical
factors inherent in organ culture vs. cell culture may also have
influenced these results.
The documentation of GPIbα expression by dermal dendrocytes
and its modulation by mast cell degranulation adds further credence
to the notion that under conditions such as inflammation and repair,
these cells may interact with von Willebrand factor and, possibly,
thrombin within the extracellular matrix. Because mast cells are
known to degranulate avidly during the early stages of inflammation
(Waldorf et al, 1991) and wound healing (Murphy et al, 1990), the
observations reported herein further support their functional linkage
to dermal dendrocytes. Although GPIbα is an integral membrane
protein (Fig 3), little is known regarding the cell biology of its
expression and regulation. The finding of cytoplasmic GPIbα
staining by immunoelectron microscopy raises the possibility of cyto-
plasmic to cell membrane transport of this molecule, particularly
when skin is activated during inflammation and repair. Major ques-
tions remain unanswered regarding the biosynthetic capability of
dermal dendrocytes for GPIbα production, and factor(s) responsible
for mast cell-induced upregulation of this membrane receptor on
dermal dendrocytes. Studies are underway to address these import-
ant issues.
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